Pam2CSK4

• UNSPSC Description:

  Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages[1][2][3].

• Target Antigen:

  Toll-like Receptor (TLR)

• Type:

  Peptides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pam2csk4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)[C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CSC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)=O)=O)=O

• Molecular Weight:

  1271.82

• References & Citations:

  [1]Parra-Izquierdo I, et al. The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. Front Immunol. 2021 Aug 30;12:729951.|[2]Kulsantiwong P, et al. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264.7. Inflamm Res. 2017 Oct;66(10):843-853.|[3]Kaur A, et al. An efficient and scalable synthesis of potent TLR2 agonistic PAM2CSK4. RSC Adv. 2018 Mar 5;8(18):9587-9596.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  868247-72-7